Skip to main content

CytRx Faces Nasdaq Delisting Hearing

NEW YORK, April 28 (GenomeWeb News) - CytRx faces a May 13 hearing before the Nasdaq Qualifications Panel over a possible delisting of the company's common stock from the Nasdaq Small Cap market.

 

Los Angeles-based CytRx failed to file a Form 10-K annual report for 2003 and is working with an accounting firm to complete an audit of its 2003 financial statements with plans to file the form "as expeditiously as possible," the company said in a statement yesterday.

 

Additionally, the company said that Araios, its Worcester, Mass.-based subsidiary, will change its name to CytRx Laboratories.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.